{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:17:10Z","timestamp":1790691430455,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2014,9,20]],"date-time":"2014-09-20T00:00:00Z","timestamp":1411171200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1007\/s40265-014-0296-3","type":"journal-article","created":{"date-parts":[[2014,9,19]],"date-time":"2014-09-19T04:44:30Z","timestamp":1411101870000},"page":"1829-1836","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Eliglustat: First Global Approval"],"prefix":"10.1007","volume":"74","author":[{"given":"Raewyn M.","family":"Poole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,20]]},"reference":[{"issue":"Suppl 1","key":"296_CR1","first-page":"77","volume":"11","author":"NJ Weinreb","year":"2013","unstructured":"Weinreb NJ. Oral small molecule therapy for lysosomal storage diseases. Pediatr Endocrinol Rev. 2013;11(Suppl 1):77\u201390.","journal-title":"Pediatr Endocrinol Rev."},{"issue":"9","key":"296_CR2","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1177\/1060028013500469","volume":"47","author":"LL Bennett","year":"2013","unstructured":"Bennett LL, Mohan D. Gaucher disease and its treatment options. Ann Pharmacother. 2013;47(9):1182\u201393.","journal-title":"Ann Pharmacother."},{"issue":"6","key":"296_CR3","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1182\/blood-2010-05-285163","volume":"116","author":"J Szer","year":"2010","unstructured":"Szer J. The substrate is down: is the IV out? Blood. 2010;116(6):860\u20131.","journal-title":"Blood."},{"issue":"8","key":"296_CR4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1358\/dof.2010.035.08.1505566","volume":"35","author":"JA Shayman","year":"2010","unstructured":"Shayman JA. Eliglustat tartrate: Glucosylceramide synthase inhibitor treatment of type 1 gaucher disease. Drugs Future. 2010;35(8):613\u201320.","journal-title":"Drugs Future."},{"key":"296_CR5","first-page":"46","volume":"124","author":"JA Shayman","year":"2013","unstructured":"Shayman JA. The design and clinical development of inhibitors of glycosphingolipid synthesis: will invention be the mother of necessity? Trans Am Clin Climatol Assoc. 2013;124:46\u201360.","journal-title":"Trans Am Clin Climatol Assoc."},{"issue":"5","key":"296_CR6","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood.V82.5.1402.1402","volume":"82","author":"SM Richards","year":"1993","unstructured":"Richards SM, Olson TA, McPherson JM. Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase. Blood. 1993;82(5):1402\u20139.","journal-title":"Blood."},{"issue":"6","key":"296_CR7","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","volume":"93","author":"M Rosenberg","year":"1999","unstructured":"Rosenberg M, Kingma W, Fitzpatrick MA, et al. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood. 1999;93(6):2081\u20138.","journal-title":"Blood."},{"key":"296_CR8","unstructured":"US Food and Drug Administration. FDA approves new drug to treat a form of Gaucher disease [media release]. 19 Aug 2014."},{"key":"296_CR9","unstructured":"Genzyme Corporation. CERDELGA (eliglustat) Prescribing Information. 2014. http:\/\/cerdelga.com\/pdf\/cerdelga_prescribing_information.pdf . Accessed 15 Sept 2014."},{"key":"296_CR10","unstructured":"Genzyme Corporation. FDA Grants Priority Review for Genzymes Cerdelga(Tm) (eliglustat), an Investigational Oral Therapy for Gaucher Disease [media release]. 11 Dec 2013."},{"key":"296_CR11","unstructured":"Genzyme Corporation. FDA Approves Genzymes Cerdelga(Tm) (eliglustat) Capsules [media release]. 19 Aug 2014."},{"key":"296_CR12","unstructured":"Sanofi. Sanofi: solid sales and business EPS growth at CER [media release]. 31 July 2014. http:\/\/sanofi.mediaroom.com\/2014-07-31-Sanofi-Solid-Sales-and-Business-EPS-Growth-at-CER ."},{"key":"296_CR13","unstructured":"Sanofi. Sanofi Q3 2013 Marks the End of the Patent Cliff Period [media release]. 30 Oct 2013."},{"key":"296_CR14","unstructured":"Sanofi-Aventis. Sanofi-Aventis Completes Acquisition of Genzyme Corporation [media release]. 8 Apr 2011."},{"key":"296_CR15","unstructured":"Sanofi. United States Securities and Exchange Commission Washington, DC 20549 FORM 20-F (2012). 2013. http:\/\/www.sanofi.com\/Images\/31972_20-F_2012_V2.pdf . Accessed 05 Sept 2014."},{"issue":"5","key":"296_CR16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1177\/0091270010372387","volume":"51","author":"MJ Peterschmitt","year":"2011","unstructured":"Peterschmitt MJ, Burke A, Blankstein L, et al. Safety, tolerability, and pharmacokinetics of eliglustat tartrate (Genz-112638) after single doses, multiple doses, and food in healthy volunteers. J Clin Pharmacol. 2011;51(5):695\u2013705.","journal-title":"J Clin Pharmacol."},{"issue":"6","key":"296_CR17","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1182\/blood-2010-03-273151","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood. 2010;116(6):893\u20139.","journal-title":"Blood."},{"issue":"4","key":"296_CR18","first-page":"176","volume":"1","author":"ML Hard","year":"2012","unstructured":"Hard ML, Puga AC, Ross L, et al. A phase 1 study evaluating the effect of eliglustat on the pharmacokinetics, safety and tolerability of digoxin in healthy subjects [abstract no. 1384434]. Clin Pharmacol Drug Dev. 2012;1(4):176.","journal-title":"Clin Pharmacol Drug Dev."},{"key":"296_CR19","unstructured":"Packman S, Amato D, Dasouki M, et al. ENGAGE: A phase 3, randomized, double-blind, placebo-controlled, multi-center study to investigate the efficacy and safety of eliglustat in adults with gaucher disease type 1 (GD1): 9 month results [abstract no. 2276F]. In: 63rd American Society of Human Genetics Annual Meeting; 22 October 2013: Boston."},{"issue":"2 SUPPL. 1","key":"296_CR20","first-page":"S268","volume":"36","author":"M Dasouki","year":"2013","unstructured":"Dasouki M, Lukina E, Ben Dridi MF, et al. Effects of oral eliglustat on bone disease in Gaucher disease type 1: Results from the randomized, placebo-controlled engage trial [abstract no. P-597]. J Inherit Metab Dis. 2013;36(2 SUPPL. 1):S268.","journal-title":"J Inherit Metab Dis"},{"key":"296_CR21","unstructured":"Burrow TA, Balwani M, Cox TM, et al. Encore: a randomized, controlled, open-label non-inferiority study comparing eliglustat to imiglucerase in gaucher disease type 1 patients on enzyme replacement therapy who have reached therapeutic goals [abstract no. 3468]. In: 55th Annual Meeting and Exposition of the American Society of Hematology; 7 December 2013: New Orleans."},{"issue":"20","key":"296_CR22","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1182\/blood-2010-06-293902","volume":"116","author":"E Lukina","year":"2010","unstructured":"Lukina E, Watman N, Arreguin EA, et al. Improvement in hematological, visceral, and skeletal manifestations of Gaucher disease type 1 with oral eliglustat tartrate (Genz-112638) treatment: 2-year results of a phase 2 study. Blood. 2010;116(20):4095\u20138.","journal-title":"Blood."},{"key":"296_CR23","doi-asserted-by":"crossref","unstructured":"Lukina E, Peterschmitt J, Watman N, et al. Eliglustat tartrate, a novel investigational oral substrate reduction therapy for gaucher disease type 1: updated phase 2 results [abstract no. 3791]. In: Blood Conference: 52nd Annual Meeting of the American Society of Hematology, ASH. 2010;116(21).","DOI":"10.1016\/j.ymgme.2011.11.132"},{"issue":"Suppl 3","key":"296_CR24","first-page":"S202","volume":"34","author":"AC Puga","year":"2011","unstructured":"Puga AC, Lukina E, Watman N, et al. Biomarker responses after 3\u00a0years of treatment with eliglustat, an investigational oral therapy for gaucher disease type 1 (GD1) [abstract no. P-375]. J Inherit Metab Dis. 2011;34(Suppl 3):S202.","journal-title":"J Inherit Metab Dis."},{"key":"296_CR25","doi-asserted-by":"crossref","unstructured":"Peterschmitt MJ, Lukina E, Watman N, et al. Eliglustat, an investigational oral therapy for gaucher disease type 1: phase 2 results after 4\u00a0years of treatment [abstract no. 1038]. In: Blood Conference: 54th Annual Meeting of the American Society of Hematology, ASH. 2012;120(21).","DOI":"10.1182\/blood.V120.21.1038.1038"},{"key":"296_CR26","doi-asserted-by":"crossref","unstructured":"Peterschmitt MJ, Lukina E, Watman N, et al. Eliglustat, an investigational oral therapy for Gaucher disease type 1: Phase 2 results after 3\u00a0years [abstract no. 1104]. In: Blood Conference: 53rd Annual Meeting of the American Society of Hematology, ASH. 2011;118(21).","DOI":"10.1182\/blood.V118.21.1104.1104"},{"key":"296_CR27","doi-asserted-by":"crossref","unstructured":"Kamath RS, Lukina E, Watman N, et al. Skeletal improvement in patients with Gaucher disease type 1: a phase 2 trial of oral eliglustat. Skeletal Radiol. 2014. doi: 10.1007\/s00256-014-1891-9 .","DOI":"10.1007\/s00256-014-1891-9"},{"key":"296_CR28","unstructured":"Mankoski R, Taylor JS, Marulkar S, et al. Clinical response to eliglustat in treatment-naive patients with gaucher disease type 1: post hoc comparison to imiglucerase in a real-world setting [abstract no. 130]. In: American College of Medical Genetics Annual Clinical Genetics Meeting; 25 May 2014: Nashville."},{"key":"296_CR29","unstructured":"Mankoski R, Peterschmitt J, Puga AC, et al. The adverse event profile of eliglustat for the treatment of gaucher disease type 1: results from a pooled analysis of four trials [abstract no. 2275T]. In: 63rd American Society of Human Genetics Annual Meeting; 22 October 2013: Boston."},{"key":"296_CR30","unstructured":"Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease who have reached therapeutic goals with enzyme replacement therapy (ENCORE) [ClinicalTrials.gov identifier NCT00943111]. US National Intitutes of Health, ClinicalTrials.gov. 2009. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00943111?term=eliglustat&rank=7 . Accessed 03 Sept 2014."},{"key":"296_CR31","unstructured":"Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease (ENGAGE) [ClinicalTrials.gov identifier NCT00891202]. US National Institutes of Health, ClinicalTrials.gov. 2009. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00891202?term=eliglustat&rank=4 . Accessed 03 Sept 2014."},{"key":"296_CR32","unstructured":"Genzyme Corporation. A study of eliglustat tartrate (Genz-112638) in patients with gaucher disease to evaluate once daily versus twice daily dosing (EDGE) [ClinicalTrials.gov identifier NCT01074944]. US National Institutes of Health, ClinicalTrials.gov. 2010. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT01074944?term=eliglustat&rank=6 . Accessed 03 Sept 2014."},{"key":"296_CR33","unstructured":"Genzyme Corporation. A study of the efficacy and safety of eliglustat tartrate (Genz-112638) in type 1 gaucher patients [ClinicalTrials.gov identifier NCT00358150]. US National Institutes of Health, ClinicalTrials.gov. 2006. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00358150?term=eliglustat&rank=5 . Accessed 03 Sept 2014."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0296-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0296-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0296-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,24]],"date-time":"2020-08-24T13:26:14Z","timestamp":1598275574000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0296-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,20]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["296"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0296-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,20]]}}}